Soleno Therapeutics is committing up to $5 million to accelerate progress toward a cure for Prader-Willi syndrome by funding groundbreaking genetic research.
This new initiative builds on years of groundwork made possible by the PWS community through FPWR-funded research. With your support, FPWR has worked alongside scientists to map the PWS region of chromosome 15, understand its impact on key biological processes, and explore new technologies that could one day correct those changes. Soleno’s program will take these discoveries a step further, providing the speed, funding, and expertise needed to move the best ideas toward real treatments.
Led by Dr. Anish Bhatnagar, CEO and Chairman, and Dr. Neil Cowen, Senior Vice President of Drug Development, Soleno will form an expert advisory board to guide funding decisions and advance the most scientifically sound and transformative projects.
This initiative complements FPWR’s mission to drive innovative research and bold ideas that improve the lives of those with PWS. Together, efforts like these are paving a powerful pathway from basic discovery to clinical solutions that bring us closer to life-changing treatments and, ultimately, a cure for PWS.
▶️ Dr. Anish Bhatnagar, Soleno Therapeutics CEO and Chairman, shared this exciting news while accepting FPWR’s Champion of Hope Award at the 2025 Live Life Full Celebration earlier this month.
